Landscape of genetic alterations affecting cancer genes in primary and advanced malignant phyllodes tumours
- 3 June 2026
- journal article
- Published by Wiley in Histopathology
- Vol. 89 (4) , 603-613
Abstract
Background: Malignant phyllodes tumours (MPT) are aggressive breast fibroepithelial neoplasms. Their rarity has limited their genetic characterization, and associations with genetic ancestry and progression drivers remain poorly understood. Prior studies suggest two evolutionary pathways according to MED12 mutational status. We sought to determine the repertoire of somatic genetic alterations in cancer genes in primary versus metastatic/recurrent MPTs, and according to MED12 mutational status and genetic ancestry. Materials and methods: We analysed the paired tumour‐normal targeting sequencing data (up to 505 cancer‐related genes) of 31 MPTs (primary, n = 20; metastatic/recurrent, n = 11). Results: Metastatic/recurrent MPTs harboured a numerically higher frequency of genetic alterations in CDKN2A/2B (55% vs. 25%). Moreover, analysis of an MPT case with paired primary and metastatic samples revealed a CDKN2A/2B homozygous deletion restricted to the metastatic sample, suggesting a role for CDKN2A/2B in progression. Compared with MED12 ‐wild type MPTs, MED12 ‐mutant MPTs had higher tumour mutation burden ( P = 0.002), frequency of TERT promoter (82% vs. 35%; P = 0.02) and RB1 mutations (45% vs. 5%; P = 0.01). Genetic alterations in the PI3K pathway, including PIK3CA and PTEN , were only present in MED12 ‐wild type MPTs, and absent in MED12 ‐mutant cases (15% vs. 0%; P > 0.05). Furthermore, genetic alterations in EGFR were restricted to MPTs from patients of European genetic ancestry and absent in those of Asian ancestry (43% vs. 0%; P > 0.05). Conclusions: Taken together, the repertoire of genetic alterations in primary and metastatic/recurrent MPTs shows overlap, and CDKN2A/2B homozygous deletions may play a role in progression. Additionally, molecular profiles of MPTs may vary according to genetic ancestry and MED12 mutational status.Keywords
This publication has 34 references indexed in Scilit:
- MED12-STAT1-TAP2 axis regulates CD8 + T cell cytotoxicity and mediates immunotherapy outcome in non-small cell lung cancerFunctional & Integrative Genomics, 2025
- Phyllodes tumor of the breast: Race-related differences in presentation, pathology and prognosisClinical Imaging, 2025
- Management of phyllodes tumor: A systematic review and meta-analysis of real-world evidenceInternational Journal of Surgery, 2022
- Racial‐ethnic variations in phyllodes tumors among a multicenter United States cohortJournal of Surgical Oncology, 2022
- The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeuticsCancer, 2019
- Genomic characterisation of breast fibroepithelial lesions in an international cohortThe Journal of Pathology, 2019
- Comprehensive genomic profiling of malignant phyllodes tumors of the breastBreast Cancer Research and Treatment, 2017
- Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progressionThe Journal of Pathology, 2015
- Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groupsBreast Cancer Research and Treatment, 2014
- A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra‐tumoral genetic heterogeneity and new genetic changes on recurrenceThe Journal of Pathology, 2008